Clinical and Genomic Evolution of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections over Two Time Periods at a Tertiary Care Hospital in South India: A Prospective Cohort Study

[1]  N. Thomson,et al.  Colonization dynamics of extended-spectrum beta-lactamase-producing Enterobacterales in the gut of Malawian adults , 2022, Nature Microbiology.

[2]  V. Cooper,et al.  Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice , 2022, Nature Microbiology.

[3]  B. Veeraraghavan,et al.  Hybrid Plasmids Encoding Antimicrobial Resistance and Virulence Traits Among Hypervirulent Klebsiella pneumoniae ST2096 in India , 2022, Frontiers in Cellular and Infection Microbiology.

[4]  Christos G Gogos,et al.  Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study. , 2020, The Journal of antimicrobial chemotherapy.

[5]  A. Farcomeni,et al.  Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Rybak,et al.  Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam , 2020, Infectious Diseases and Therapy.

[7]  K. Holt,et al.  Population genomics of Klebsiella pneumoniae , 2020, Nature Reviews Microbiology.

[8]  P. Póvoa,et al.  Impact of immunosuppression on incidence, aetiology and outcome of ventilator-associated lower respiratory tract infections , 2018, European Respiratory Journal.

[9]  L. Nabarro,et al.  Whole genome analysis of hypervirulent Klebsiella pneumoniae isolates from community and hospital acquired bloodstream infection , 2018, BMC microbiology.

[10]  S. Richter,et al.  Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  R. Laxminarayan,et al.  Antibiotic Resistance in India: Drivers and Opportunities for Action , 2016, PLoS medicine.

[12]  M. Bassetti,et al.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. , 2015, The Journal of antimicrobial chemotherapy.

[13]  Peter Ankomah,et al.  Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections , 2014, Proceedings of the National Academy of Sciences.

[14]  L. Baddour,et al.  Predictive scoring model of mortality in Gram-negative bloodstream infection. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  E. Sampaio,et al.  Different immunosuppressive mechanisms in multi‐drug‐resistant tuberculosis and non‐tuberculous mycobacteria patients , 2013, Clinical and experimental immunology.

[16]  M. Bassetti,et al.  Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.